MERCK LOCK-OUT OF UNION EMPLOYEES AT RAHWAY, HAWTHORNE, N.J., PLANTS initially will not affect drug production at Merck Sharp & Dohme's pharmaceutical headquarters in West Point, Pa., the company maintains. Merck is operating the plants with a contingency team of salaried employees. The firm said operations at the Rahway plant, which manufactures bulk chemicals for animal and human health products, are continuing at full production. Operations at the Calgon subsidiary plant in Hawthorne are limited, Merck said, but there are no production delays. The Calgon plant produces water treatment chemicals. The lock-out at Rahway occurred after stalled negotiations with three unions -- the Oil, Chemical & Atomic Workers Internatl. Union, the Internatl. Chemical Workers Union, and the Amalgamated Clothing & Textile Workers Union. The Hawthorne facilities were closed to union employees May 6. The lock-out at the two plants occurred due to disagreements on local issues, which include work rules and jurisdictional matters. The three unions jointly represent 4,000 employees of additional Merck plants in West Point, Pa.; Danville, Pa.; Elkton, Va.; Albany, Ga., South San Francisco; and a farm in North Branch, N.J. Contract negotiations for all the plants have halted. Local issues at the other plants reportedly appeared resolvable at the time the negotiations stopped. Work at these additional six sites is continuing without a new contract. Merck plants last experienced strikes in 1969 when contract negotiations broke down over disagreements in wages and benefits. That strike involved 3,000 employees at five plants, West Point, Danville, Hawthorne, Rahway and North Branch. The present lock-out involves 730 employees at Rahway and 38 at Hawthorne. Merck U.S. employees total 16,600.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
European health systems already pay far too much for new medicines and payers will not accept higher prices to compensate for lower US prices, according to Anja Schiel, from NOMA, the Norwegian health technology assessment body.
In a somewhat surprising move, President Trump’s Federal Trade Commission is continuing a crusade to delist improper listings from the FDA’s Orange Book. Law firm Polsinelli’s chair Chad Landmon discussed the impact of the move on the generic drug industry.
Cell and gene therapy developers may not have to contend with HHS Secretary Robert F. Kennedy Jr.’s animosity like the traditional pharma industry, but his disinterest in distinguishing between the good and bad actors in the space could backfire.
